View Older Stories View More Recent Stories

Apr 21, 2021 08:30AM Genprex to Participate in CEO Roadshow Webinar Series
Apr 20, 2021 08:30AM Genprex to Receive Inaugural “License of the Year” Award from University of Pittsburgh Innovation Institute in Recognition of Advances Made with Gene Therapy Program in Diabetes
Apr 12, 2021 08:37AM Genprex (GNPX) Collaborators Report Positive Preclinical Data for REQORSA Immunogene Therapy in Non-Small Cell Lung Cancer at AACR
Apr 12, 2021 08:30AM Genprex Collaborators Report Positive Preclinical Data for REQORSA™ Immunogene Therapy in Non-Small Cell Lung Cancer at the 2021 AACR Annual Meeting
Apr 5, 2021 08:30AM Genprex to Present at the 2021 Virtual Cell & Gene Meeting on the Mediterranean
Mar 30, 2021 08:32AM Genprex (GNPX) Announces Preclinical Data for TUSC2 Immunogene Therapy in Non-Small Cell Lung Cancer to Be Featured in Two Presentations at AACR
Mar 30, 2021 08:30AM Genprex Announces Preclinical Data for TUSC2 Immunogene Therapy in Non-Small Cell Lung Cancer to Be Featured in Two Presentations at the 2021 American Association for Cancer Research Annual Meeting
Mar 24, 2021 08:30AM Genprex to Present at the Spring 2021 Oncology Investor Conference on March 29
Mar 1, 2021 08:30AM Genprex to Participate in Upcoming March Investor Conferences
Feb 9, 2021 08:31AM Genprex (GNPX) Announces $25 Million Registered Direct Offering of Common Stock
Feb 9, 2021 08:30AM Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants
Feb 8, 2021 03:30PM Genprex Announces Formation of Clinical Advisory Board
Feb 4, 2021 08:30AM Genprex Recognizes World Cancer Day
Feb 1, 2021 01:33PM Genprex (GNPX) Issues Shareholder Update
Feb 1, 2021 01:30PM Genprex Issues Shareholder Letter and Provides Corporate Update
Jan 27, 2021 08:30AM Genprex to Present at the Virtual Investor Conference Small and Microcap Showcase on February 4
Jan 21, 2021 08:30AM Genprex to Present its Cutting-Edge Gene Therapies at the MoneyShow Accredited Investors Virtual Expo
Jan 14, 2021 08:30AM Genprex to Present at NobleCon17 on January 19
Jan 13, 2021 09:00AM Genprex Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer
Dec 24, 2020 01:02PM Genprex, Inc. Announces Closing Of $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Without Warrants
Dec 22, 2020 01:15PM Genprex (GNPX) Announces $12 Million Registered Direct Offering of Common Stock
Dec 22, 2020 01:15PM Genprex, Inc. Announces $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules, Without Warrants
Dec 22, 2020 09:32AM Genprex Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA™ Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer
Dec 8, 2020 08:16AM Genprex Completes Manufacturing Technology Transfer for Novel Gene Therapy
Dec 3, 2020 08:17AM Genprex to Present at the Benzinga Global Small Cap Conference on December 8
Nov 30, 2020 02:05PM Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer
Nov 24, 2020 08:16AM Genprex to Participate at the Diamond Equity Research Emerging Growth Invitational on December 1
Nov 11, 2020 08:16AM Genprex to Participate in Panel at Life Sciences Summit on November 17
Nov 10, 2020 08:17AM Genprex Strengthens Scientific Advisory Board with Appointment of Lead Researcher of University of Pittsburgh, George K. Gittes, MD
Oct 30, 2020 08:17AM Genprex Unveils New Branding for Upcoming Combination Clinical Trials in Non-Small Cell Lung Cancer
Oct 29, 2020 08:20AM Genprex (GNPX) Receives Conditional FDA Acceptance of Proprietary Name REQORSA for Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer
Oct 29, 2020 08:16AM Genprex Receives Conditional FDA Acceptance of Proprietary Name REQORSA™ for Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer
Oct 26, 2020 08:16AM Genprex Promotes Eric Chapdelaine to Vice President of Manufacturing
Oct 7, 2020 08:17AM Genprex to Present at Zooming with LD Micro on October 14, 2020
Oct 6, 2020 08:16AM Genprex to Present at the Alliance for Regenerative Medicine’s Virtual Cell and Gene Meeting on the Mesa
Sep 21, 2020 08:17AM Genprex Names Seasoned IP Executive, Thomas C. Gallagher, as Senior Vice President of Intellectual Property and Licensing
Sep 2, 2020 08:17AM Genprex Appoints William E. Gannon, Jr., MD, MBA, as Vice President of Regulatory Affairs
Aug 26, 2020 08:17AM Genprex to Present at The LD 500 Virtual Conference
Aug 26, 2020 08:17AM Genprex to Present at The LD 500 Virtual Conference
Jul 31, 2020 08:17AM Genprex to Present at Proactive’s One2One Virtual Investor Forum on August 4, 2020
Jul 30, 2020 08:16AM Genprex CEO Participates in a Second-Round Live Interview on the “Big Biz Show”
Jul 21, 2020 08:17AM National Institutes of Health (NIH) Awards Research Grant of $2.59 Million to University of Pittsburgh for Diabetes Gene Therapy Technology Licensed by Genprex
Jun 29, 2020 08:16AM Genprex Added to Russell 3000® Index
Jun 25, 2020 08:18AM Genprex (GNPX) Receives USAN Approval of Non-Proprietary Name for Lead Drug Candidate
Jun 25, 2020 08:17AM Genprex Receives USAN Approval of Non-Proprietary Name for Lead Drug Candidate
Jun 24, 2020 08:16AM Genprex CEO to Interview Live on “The Big Biz Show”
Jun 16, 2020 08:17AM Genprex Expands Manufacturing Program with Aldevron to Advance Oncoprex™ Clinical Development
Jun 9, 2020 08:17AM Genprex Scheduled to Join Russell 3000® Index
Jun 8, 2020 08:17AM Genprex to Present at the MoneyShow June Virtual Event
May 28, 2020 08:17AM Genprex (GNPX) Announces Receipt of $2.5 Million in Cash from Recent Warrant Exercises
View More Recent Stories View Older Stories